Keywords: Meta-analysis; VKC; vernal keratoconjunctivitis; allergy; topical treatment ABSTRACT Aims: The aim of this study was to assess the efficacy of currently available topical drugs for vernal keratoconjunctivitis (VKC) through a meta-analysis of randomized clinical trials (RCTs). Methods: Twenty-seven RCTs (N= 2184 eyes) that had evaluated the efficacy of topical drugs for the treatment of VKC were selected according to the set criteria; ten of these trials were suitable for statistical analysis and were enrolled in the meta-analysis. Articles published up to December 2005 were identified from the following data sources: Medline, Embase, Lilacs, the Cochrane Controlled Trials Register, and references from relevant articles. Articles in any language published with an English abstract, were screened and those selected for inclusion were written in English, French, German, Italian, Portuguese or Spanish. Quality of trials was assessed by the Delphi list. Statistical analysis was performed using STATA software. Results: Significant improvement in all signs and symptoms, except photophobia, was observed after topical treatment for active VKC, independent of the type of treatment. Comparison of the efficacy of different drugs was not possible due to a lack of standardized criteria among studies.
INTRODUCTION
Vernal keratoconjunctivitis (VKC) is a recurrent bilateral chronic allergic inflammatory disease of the ocular surface affecting mainly young males in the first decade of life. Diagnosis is based on signs and symptoms including itching, photophobia, sticky mucous discharge, giant papillae on the upper tarsal conjunctiva or at the limbus, superficial keratopathy, and corneal shield ulcer. An immunopathogenic mechanism has been proposed for this disease on the basis of personal or familial history of atopy, increased serum levels of total and specific IgE, the response to antiallergic therapy and the presence of several immune cells and mediators in the conjunctiva. [1] [2] [3] At present, the exact pathogenic mechanism has not been completely identified. In spite of its generally benign and self-limited presentation, therapeutic measures are required to control signs and symptoms of the disease and to avoid the long-standingpermanent inflammatory sequelae that may lead to fibrovascular reaction, new collagen deposition, tissue remodeling and permanent visual damage. [1] [2] [3] Several reports indicate that topical anti-inflammatory and anti-allergic eye drops are the mainstay of treatment for VKC, however a gold standard treatment has not yet been established for this disease. [4, 5] In the present report, we systematically reviewed RCTs and conducted a meta-analysis of the combined results on all available topical drugs for VKC, including antihistamines, mast cell stabilizers, NSAIDs, corticosteroids, immunomodulators and antimitotics, to confirm that topical therapy is an effective treatment in patients with VKC and to establish which therapeutic regimen is most suitable for this condition. To obtain satisfactory homogeneity, we adopted strict eligibility criteria.
MATERIALS AND METHODS

Literature search
Six observers, divided in three groups of two, independently performed a literature search of all publication years up to December 2005. The articles were identified through a computerized search in the Cochrane Controlled Trial Register-CENTRAL/CCTR (which contains the Cochrane Eyes and Vision Group trials register) on the Cochrane Library, MEDLINE, EMBASE and LILACS (Latin American and Caribbean Health Sciences Literature Database). The search strategy was used to identify randomized clinical trials, as recommended by the Cochrane Collaboration. [6] Keywords/Search terms for disease were: vernal and keratoconj*, explode vernal keratoconjunctivitis/ all subheadings, vkc/ all subheadings. Keywords/Search terms for medications were: antihistamine, antazoline, azelastine, levocabastine, emedastine, pheniramine; mast cell stabilizer, sodium cromoglycate, lodoxamide, nedocrimil, spaglumic acid; olopatadine, ketotifen, epinastine; corticosteroid, betamethasone, clobethasone, dexamethasone, fluorometholone, hydrocortisone, loteprednol etabonate, medrysone, prednisolone, rimexolone; NSAID, fluorbiprofen, ketorolac, ibuprofen, indomethacin, pranoprofen; cyclosporine; antimitotic, mitomycin-C.
In addition, linked references in all relevant articles as well as the reviewer's personal collections of articles on vernal keratoconjunctivitis were searched. The search resulted in a total of 333 abstracts.
Inclusion and exclusion criteria
Articles potentially eligible for inclusion in this meta-analysis were double-masked randomized clinical trials on topical therapy for vernal keratoconjunctivitis published up to December 2005, written in English, French, German, Italian, Portuguese or Spanish. Additional inclusion criteria for the trials were: follow up of at least two weeks and adequate wash-out from previous treatment. Articles were excluded if they did not satisfy one or more inclusion criteria, or if they were irretrievable after performing all available search strategies, including request to authors and editors.
The article's eligibility was initially determined by evaluating the titles, abstracts and MeSH (medical subject headings). Four observers divided in two groups of two examined all the retrieved 333 abstracts to consider their eligibility. After matching the decisions of the two groups, 285 articles were excluded because they were either not on topical treatments or they were related to different kinds of ocular and/or systemic allergy. The remaining 48 complete articles were obtained and printed to identify whether they were randomized clinical trials. Four articles were excluded because they did not match this criterion.
To select the trials to be included in this meta-analysis, the remaining 44 potentially eligible trials were distributed to four researchers divided into two groups of two. The observers were blinded to the names of the authors and institutions, the name of the journals, the sources of funding, and the sponsors of the studies. The observers of each group were also blinded to the decisions of the other group and trial selection was matched between them. Seventeen trials were excluded because they did not match one or more inclusion criteria (not double-masked; follow-up shorter than two weeks; no/inadequate wash-out from previous treatment/s).
All the remaining 27 trials were included in the systematic review, while only ten of them were included in the meta-analysis because they presented comparable data suitable for quantitative statistical analysis (Figure1).
Data extraction
Data were extracted from each article using a standardized form.
Quality assessment
Methodological quality was evaluated using the Delphi list. [7] Each item in this quality list had the same weight. For each publication, a quality score was calculated where "YES" was scored as 1 point for a certain quality item and "NO" and "DO NOT KNOW" were scored as 0 points.
Outcome measures
Mean change from baseline to the end of treatment was identified for the following parameters: itching, tearing, photophobia, hyperemia, tarsal papillae, limbal disease and corneal involvement.
Statistical analysis
STATA software [8] was used to analyze the data. When two or more studies reported comparable results for the same outcome, those results were presented in an analysis table. The forest plots used were generated by STATA software. In a forest plot, the results of combined studies are shown as squares centered on the standardized mean difference for the specified outcome for each study. The horizontal line through the square indicates the 95% confidence interval (CI) for the mean. At the bottom of each plot there is a diamond, the center and extent of which indicates the mean and CI of the pooled results from all the studies. If the diamond is clear of the central vertical line of no effect, the data are considered significant at the stated level (in this study, 5%). The outcomes in this meta-analysis have all been reported such that a diamond to the left of the central line indicates an effect in favour of topical treatment for VKC.
We tested the heterogeneity between studies using the Chi-square test, with significant heterogeneity (p<.05) precluding meta-analysis.
RESULTS
Description of studies
The 27 studies included in the systematic review dated from 1972 to 2003; 22 of these were published in ophthalmic journals. Eleven trials were performed in Europe, seven in Asia, five in America, three in Africa and one was a multicentered study conducted in Europe and America. There were seven multicentered studies and all were randomized clinical trials. Twenty-four studies were double-masked and three were single-masked; seventeen were placebo-controlled and the mean follow-up was 59.5 ± 74.2 days. Mean wash-out from previous therapies was 18.3 ± 36.9 days. A total of 1092 patients and 2184 eyes were enrolled in the studies. Mean age was 13.3 ± 4.5 years old. Severity of disease was considered only in 13 of the 27 studies and only five trials reported in which period of the year the study was conducted. Four studies were sponsored by a pharmaceutical company. Nineteen of these 27 studies, of which two with three groups of participants, compared mast cell stabilizers to another drug: ten groups versus placebo; eight versus another mast cell stabilizer; two versus corticosteroids; one versus an anithistaminic. Five studies compared an immunomodulator to another drug: four versus placebo and one versus a mast cell stabilizer. Two studies, of which one with three groups of participants, compared a NSAID to another drug: two versus placebo and one versus corticosteroids. One study compared an antimitotic drug to placebo. (Table 1 Two hundred and forty-five patients were enrolled in these 10 trials. Mean age was 13.3 ± 2.8 years old. The design and general characteristics of these studies are listed in Table 3 . There was no significant difference in the quality of the studies as assessed by the Delphi List, and therefore the weight of each single study was primarily based on the number of participants.
Outcomes reported and evaluated in our meta-analysis included a total score for signs and symptoms and single scores for the following specific signs and symptoms: itching, tearing, photophobia, hyperemia, tarsal papillae, limbal disease and corneal involvement.
Efficacy of topical treatment for vernal keratoconjunctivitis
The effect of topical mast cell stabilizers, immunomodulators, NSAIDs and antimitotic agents in controlling signs and symptoms of patients with VKC, compared to placebo, was evaluated in the trials included in both the systematic review and the meta-analysis.
Systematic review of the initial 27 studies indicated a positive effect of common antiallergic eye drops in reducing signs and symptoms of the disease. (Table 1) All the drugs tested in these 27 studies were found to be safe, well tolerated (except only transient mild burning and tearing upon instillation of cyclosporine eye drops) and more effective than placebo. The greater number of studies (20) evaluated the efficacy of common anti-allergic eye drops (levocabastine, lodoxamide, mipragoside, NAAGA, nedocromil sodium, sodium/disodium cromoglycate). Among these, lodoxamide appeared to be the most effective. Compared to anti-allergic drugs, however, corticosteroids (1 study) were more effective while immunomodulators (1 study) did not show a statistically significant difference in reduction of signs and symptoms of the disease.
To demonstrate whether the efficacy of these drugs in reducing signs and symptoms of active disease was significant, a meta-analysis was conducted on the ten trials that presented comparable data suitable for statistical analysis.
The combined results of these ten RCTs included in the meta-analysis clearly demonstrated a positive effect favouring improvement of signs and symptoms in active VKC after topical therapy, independent of the pharmaceutical class for the following clinical variables: total signs and symptoms, itching, tearing, corneal involvement, limbal disease and hyperaemia. A positive effect in reducing tarsal papillae was also demonstrated, however it was only slightly significant (p=.047). There was a trend towards improvement also in photophobia, but it was not statistically significant (p=.105). (Table 4 and Figures 2-4 Comparison among different pharmaceutical classes and drugs was not possible due to the small number of available RCTs on the subject and the great variability in assessment of outcome measures to evaluate the effects of topical treatment for VKC
)
DISCUSSION
A systematic review of randomized clinical trials aimed at evaluating topical therapies for the treatment of VKC indicated that all the common anti-allergic eye drops are effective in reducing signs and symptoms of the disease. Topical anti-allergic agents used by VKC patients are the same as those used to treat other forms of allergic conjunctivitis since the exact pathogenesis of VKC is unknown and there is, thus, no specific treatment. [3] Although these topical drugs do not completely control the disease, they have been shown to be effective in reducing signs and symptoms during active phases by interfering with at least one pathogenic mechanism. [5, 36] Even placebo is known to have beneficial effects, improving signs and symptoms by acting as a lubricant of the ocular surface. Nevertheless, several reports indicate that some patients do not respond to anti-allergic treatment and respond only to topical steroids: in fact, particularly moderate to severe cases may not respond to common anti-allergic treatments and may also require new therapeutical strategies.
These observations underlined the need of a meta-analysis to evaluate the efficacy of all the currently available topical treatments for VKC: to undertake this meta-analysis, we selected only clinical trials conducted on patients diagnosed with VKC and we used strict eligibility criteria to evaluate the combined results of comparable RCTs only. We found a very limited number of studies specifically focused on VKC, and even fewer were considered suitable. Clinical trials of antiallergic agents for the treatment of other types of ocular allergies were excluded.
Despite the considerable available literature providing possible protocol standards for the assessment of drug efficacy, [37, 38] the majority of studies on VKC were not randomized, presented inadequate control groups, and most were not multicentered. As a result, small samples sizes made it difficult to detect small to moderate, but potentially clinically relevant, differences between the treatments tested. These limitations also made it impossible to compare different pharmaceutical classes and/or individual drugs used for the treatment of this disease.
Heterogeneity among the trials' findings lent uncertainty as to whether it was appropriate to pool and summarize the selected studies. However, heterogeneity was tested in this meta-analysis, and was found to not be statistically significant, indicating that pooling of the studies' results was methodologically correct. [39, 40] Overall, this meta-analysis of RCTs demonstrates that currently available topical therapies (mast cell stabilizers, immunomodulators, NSAID's and antimitotic) are significantly more effective than placebo for treating most signs and symptoms of vernal keratoconjunctivitis. However, there is a lack of evidence supporting the recommendation of one specific type of medication for treating this disorder.
These findings indicate that, to study a homogeneous group of patients, general consensus on the clinical stages of VKC should be defined. This disease is of widely varying severity due to differences in individual sensitivity, geographical localization, time of observation, and many environmental factors that greatly influence the outcome of clinical trials. We suggest that more detailed diagnostic criteria be added to protocols to better define and exclude other allergic entities and to better define the clinical stages of VKC. Table 2 . Baseline characteristics of the randomized clinical trials evaluating the efficacy of topical treatment for vernal keratoconjunctivitis. Table 3 . Design and general characteristics of selected randomized clinical trials evaluating the efficacy of topical treatment for vernal keratoconjunctivitis. Table 4 . Combined results from randomized clinical trials examining the absolute change in specific signs and symptoms after topical treatment versus placebo.
